drugset / Trial / NCT05687253
Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Assessment of Intubation conditions following administration of neuromuscular blocking agents; BX1000 (investigational) or rocuronium (active control).
Timeline
- Start
- 2022-10-25
- Primary completion
- 2023-04-10
- Completion
- 2023-05-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BX1000 | Unknown | 0.15 mg/kg | Intravenous |
| Subject | BX1000 | Unknown | 0.25 mg/kg | Intravenous |
| Subject | BX1000 | Unknown | 0.35 mg/kg | Intravenous |
| Comparator | Rocuronium | Other / unclassified | 0.6 mg/kg | Intravenous |
Indications
No indication recorded.